pc 버전으로 이동 중 [시장보고서]유전자 독성 시험 시장 규모, 점유율, 동향 분석 리포트 : 유형별(인비트로, 인비보), 제품별(시약 및 소모품, 어세이, 서비스), 용도별, 지역별, 부문별 예측(2022-2030년)
유전자 독성 시험 시장 규모, 점유율, 동향 분석 리포트 : 유형별(인비트로, 인비보), 제품별(시약 및 소모품, 어세이, 서비스), 용도별, 지역별, 부문별 예측(2022-2030년)
Genetic Toxicology Testing Market Size, Share & Trends Analysis Report By Type (In-vitro, In-vivo), By Product (Reagents & Consumables, Assays, Services), By Application, By Region, And Segment Forecasts, 2022 - 2030
상품코드 : 1133325
리서치사 : Grand View Research, Inc.
발행일 : 2022년 09월
페이지 정보 : 영문 150 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,950 ₩ 8,218,000
Unprintable PDF (Single User License)
US $ 6,950 ₩ 9,599,000
Printable PDF (5-User License)
US $ 8,950 ₩ 12,361,000
Printable PDF (Enterprise License)


한글목차

유전자 독성 시험 시장의 성장과 동향

Grand View Research, Inc.의 새로운 리포트에 따르면 세계의 유전자 독성 시험 시장 규모는 2030년까지 35억 7000만 달러에 달할 것으로 예측되고 있습니다. 이 시장은 2022-2030년 CAGR 12.7%로 확대할 것으로 예측됩니다. 맞춤형 의약품의 사용량 증가와 세계에서 세포·유전자 치료의 발전이 유전자 독성에 대한 수요를 높이고 있습니다.

목차

제1장 조사 방법

제2장 시장의 정의

제3장 주요 요약

제4장 세계의 유전자 독성 시험 시장 : 변수, 동향 및 범위

제5장 유전자 독성 시험 시장 : 부문 분석, 유형별, 2018-2030년(100만 달러)

제6장 유전자 독성 시험 시장 : 부문 분석, 제품별, 2018-2030년(100만 달러)

제7장 유전자 독성 시험 시장 : 부문 분석, 애플리케이션별, 2018-2030년(100만 달러)

제8장 유전자 독성 시험 시장 : 부문 분석, 지역별, 2018-2030년(100만 달러)

제9장 경쟁 구도

KSA 22.10.17
영문 목차

영문목차

Genetic Toxicology Testing Market Growth & Trends:

The global genetic toxicology testing market size is expected to reach USD 3.57 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to expand at a CAGR of 12.7% from 2022 to 2030. The rising usage of personalized medicines, combined with the development of cell and gene therapy across the globe is enhancing the demand for genotoxicity. For instance, the U.S. FDA has designed guidance documents for the manufacturers of cell and gene therapy. According to the guidance, information on the identification of toxicities and physiologic parameters in preclinical studies can assist in guiding clinical monitoring for the investigational product.

Increasing implementation of pharmacogenomics to support personalized medicine usage and reduced risk of adverse drug toxicity is considered to have a significant impact on the growth of the industry. Moreover, organizations, such as the Dutch Pharmacogenetics Working Group (DPWG), Clinical Pharmacogenetics Implementation Consortium (CPIC), the French National Network of Pharmacogenetics, and the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), have issued clinical guidelines with a primary focus on the pharmacogenomics testing interpretation and recommendation on therapeutic specific drug-gene pairs.

Similarly, the market players are indulging in various strategies to expand their footprint in multiple segments. For instance, in November 2021, Labcorp announced the acquisition of Toxikon, a Contract Research Organization (CRO) with offerings in nonclinical testing services. Through this acquisition, Labcorp is anticipated to strengthen its toxicology business and Toxikon's location enables Labcorp to engage with known biotech and pharmaceutical companies in the region for non-clinical work.

The COVID-19 pandemic is anticipated to have a neutral impact on the genetic toxicology testing market growth. Numerous researchers employed genotoxic to assess the effects of drugs against the COVID-19 virus. For instance, in September 2020, a team of researchers evaluated the impact of Chloroquine (CQ) and Hydroxychloroquine (HCQ) as prophylactic drugs against the virus. The genetic toxicology of various drugs and chemicals was assessed. Such studies using genetic toxicology testing as a tool of assessment are anticipated to support stable growth during the peak of COVID-19.

The rising demand for novel food and its imports is expected to be a contributor to market growth. Charles River Laboratories is one of the major players offering toxicology assessments on novel foods. They offer novel food analysis including genotoxicity, which consist of in vivo micronucleus test, Ames study, In Vitro Mammalian Cell Micronucleus, and in the vivo comet assay. Similarly, in January 2021, EFSA published its evaluation of insect-derived food. It is the first kind of assessment conducted by the institution on the insect product as a novel food. Every year, EFSA receives a large number of applications, consisting of herbal products based on algae foods, plants, and non-indigenous fruits.

On the other hand, the ability to retrieve information through genetic toxicology is limited. According to the Pathology Tests Explained organization, genetic tests offer information regarding the specific diseases/gene that is being tested. It does not cover information about other genetic diseases that might be present but have not been tested. Similarly, it cannot identify all the variations of genes that cause the diseases, and also it does not showcase the severity of the diseases. Hence, these limitations are anticipated to hamper the growth of the genetic toxicology industry.

Genetic Toxicology Testing Market Report Highlights:

Table of Contents

Chapter 1 Research Methodology

Chapter 2 Market Definitions

Chapter 3 Executive Summary

Chapter 4 Global Genetic Toxicology Testing Market Variables, Trends, & Scope

Chapter 5 Genetic Toxicology Testing Market - Segment Analysis, by type, 2018 - 2030 (USD Million)

Chapter 6 Genetic Toxicology Testing Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)

Chapter 7 Genetic Toxicology Testing Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)

Chapter 8 Genetic Toxicology Testing Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기